Table 3.
Response data to preoperative capecitabine therapy.
| Pathological response | Number of patients (%) | Pathological complete response rate (95% CI) |
|---|---|---|
| pCR | 0 (0) | 0 (0–13.8) |
| Not pCR | 22 (91.7) | |
| Unevaluable1 | 2 (8.3) | |
| Best overall response | Number of patients (%) | Objective response rate (95% CI) |
| Radiographic | ||
| CR | 0 (0) | 37.5 (21.2–57.3) |
| PR | 9 (37.5) | |
| SD | 11 (45.8) | |
| PD | 2 (8.3) | |
| Unevaluable1 | 2 (8.3) | |
| Clinical | ||
| CR | 3 (12.5) | 45.8 (27.9–64.9) |
| PR | 8 (33.3) | |
| SD | 11 (45.8) | |
| PD | 0 (0) | |
| Unevaluable1 | 2 (8.3) | |
| Miller–Payne | ||
| 1 | 10 (41.7) | |
| 2 | 6 (25.0) | |
| 3 | 6 (25.0) | |
| 4 | 0 (0) | |
| 5 | 0 (0) | |
| Unevaluable1 | 2 (8.3) | |
pCR, pathological complete response; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
1
Two patients were off treatment after Cycle 1.